Trial Profile

Phase IIb of VDA-1102 (Tuvatexib) in patients with Cutaneous T-cell lymphoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tuvatexib (Primary)
Indications Cutaneous T-cell lymphoma
Focus Therapeutic Use
Sponsors VidacPharma

Most Recent Events

07 Jan 2022 New trial record
20 Sep 2021 According to a Vidac Pharma media release, with the satisfied the results of the first step of this study, safety results granted this trial a dose ranging protocol authorization. This will speed up recruitment at Beilinson Hospital in Israel under the direction of Prof. Emilia Hodak and program a Phase 2B both in Israel and in Europe.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com